CD274 and hepatocellular carcinoma: At the same time, with the increasing use of immunotherapies such as immune checkpoint inhibitors Immune checkpoint inhibitors (ICIs) in other cancers, such as PD-L1 monoclonal antibody combined with VEGFR monoclonal antibody regimen has become the first-line systemic treatment regimen for advanced HCC 117, methods for hepatobiliary tumors have also entered our horizon.